NasdaqGS:SPROBiotechs
Spero Therapeutics (SPRO) Earnings Turn Positive Challenging Bearish Profitability Narratives
Spero Therapeutics (SPRO) closed FY 2025 with fourth quarter revenue of US$41.3 million and basic EPS of US$0.56, alongside trailing twelve month revenue of US$66.8 million and EPS of roughly US$0.15 that mark a shift into profitability over the period. Over recent quarters, the company has seen revenue range from US$5.4 million to US$41.3 million with quarterly EPS moving from a loss of about US$0.25 per share at the start of FY 2025 to a profit in the latest quarter, providing a clearer...